• About Us
    • News
    • Leadership
    • Contact
  • Innovation
    • Intelligent Mutagenesis
    • Pronectin™
    • Patents
  • Therapeutics
    • Oncology
    • Bi-Specific
    • ProCAR-T™
    • Others applications
  • Partnerships
  • About Us
    • News
    • Leadership
    • Contact
  • Innovation
    • Intelligent Mutagenesis
    • Pronectin™
    • Patents
  • Therapeutics
    • Oncology
    • Bi-Specific
    • ProCAR-T™
    • Others applications
  • Partnerships

 Oncology Applications

Our innovative approach focuses on the development of a diverse array of next-generation protein therapeutics including Pronectin™ cancer immunotherapies, Pronectin™ drug conjugates (PDCs), T-cell engaging Pronectin™ and bi-specific and Pronectin™, enabled chimeric antigen receptor (Pn-CAR-T ™) cell therapies.

Antibody therapeutics have revolutionized the treatment of a number of diseases including cancer and inflammation. There are more than 470 antibody therapeutics in clinical testing which is a testimony to the applications of antibody engineering that have played a major role in expanding this family of large molecule therapeutics over the past two decades. Several antibodies have now reached FDA approval and commercialization including: function blocking antibodies that target cancer cell surface receptors (e.g. anti-HER2, anti-EGFR, anti-CD2 and anti-PDL1 antibodies); Antibody-Drug Conjugates (ADCs) (e.g.: Kadcyla®, Adcetris®) and Bi-specific ADCs; Immune-check point T-cell modulators (anti-PD1 or anti-CTLA4 antibodies); Bi-specific T-cell Engagers (BITE®), Immune mobilizing monoclonal TCRs Against Cancer (ImmTACs) that recruit and activate T-cells; Engineered T-cells with Chimeric Antigen Receptors (CARs) (anti-CD19 CARs). 
Very recently, Novartis CAR-T cell therapy CTL019 was unanimously recommended for approval by FDA advisory committee to treat pediatric, young adult B-cell leukemia.

Our Pronectin™ technology and drug discovery platform that can be exploited to replace many antibody therapeutic modalities as highlighted below.

​Each of these therapeutic modalities have shown incredible potential and the opportunity to bring forth new options for better drugs in multiple ways including more selective targeting and improved manufacturability. 

1 & 8. Pronectin™ Bi-specific T-cell Engagers (Pn-BITE™),
2. Fc-Pronectin™,
3. Pronectin™ engineered Chimeric Antigen Receptor T-Cells (Pn-CAR-T™),
4. Function blocking Pronectins™ that target cancer cell surface receptors,
5. Pronectin-Drug Conjugates (PnDC™),
6. Immune-check point Pronectin™ T-cell modulators,
7. Pronectin Bi-specific Drug Conjugates (PnDC™).
Picture
✕